HC Wainwright Reduces Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Investment analysts at HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for Cabaletta Bio in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $0.87 for the year, down from their prior estimate of $0.89. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.27) per share.

CABA has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a report on Thursday, October 15th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. William Blair raised shares of Cabaletta Bio to a “strong-buy” rating in a research note on Wednesday, September 23rd. Wells Fargo & Company cut their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Finally, Citigroup cut their price target on shares of Cabaletta Bio to $8.00 and set a “buy” rating on the stock in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Cabaletta Bio Trading Down 3.3%

Shares of NASDAQ CABA opened at $1.45 on Monday. The company has a 50 day simple moving average of $2.05 and a 200 day simple moving average of $2.81. Cabaletta Bio has a 1 year low of $1.18 and a 1 year high of $4.23.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Institutional Investors Weigh In On Cabaletta Bio

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Private Advisor Group LLC raised its position in shares of Cabaletta Bio by 22.4% during the first quarter. Private Advisor Group LLC now owns 18,025 shares of the company’s stock worth $48,000 after acquiring an additional 3,300 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Cabaletta Bio by 47.6% in the third quarter. Voya Investment Management LLC now owns 31,557 shares of the company’s stock valued at $61,000 after acquiring an additional 10,180 shares during the last quarter. Legal & General Group Plc bought a new stake in Cabaletta Bio in the second quarter valued at approximately $34,000. HighTower Advisors LLC acquired a new stake in Cabaletta Bio during the 2nd quarter valued at approximately $34,000. Finally, WINTON GROUP Ltd increased its position in Cabaletta Bio by 76.5% during the 2nd quarter. WINTON GROUP Ltd now owns 27,000 shares of the company’s stock valued at $84,000 after purchasing an additional 11,700 shares during the period.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: Cabaletta presented new Phase 1/2 data for rese-cel at ACR Convergence 2026. A related report characterized the autoimmune-disease results as positive, which may reinforce investor interest in the company’s clinical program. Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026
• Positive Sentiment: HC Wainwright raised its earnings estimates across several future periods, projecting smaller per-share losses, including for fiscal 2027–2029. The firm maintained its Buy rating and $16 price target, an optimistic view that could support sentiment. Cabaletta Bio analyst coverage
• Neutral Sentiment: A short-interest report listed zero shares sold short as of November 10, making its accompanying claim of a significant increase internally inconsistent; it offers no reliable indication of short-selling pressure.
• Negative Sentiment: Citigroup lowered its price target to $8, although it retained a Buy rating. The reduced target may temper enthusiasm despite remaining above the price cited in the report. Citigroup stock recommendations

About Cabaletta Bio

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression. Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.